• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Dexlansoprazole
    1 Drug classified under this active ingredient

    All the Active Ingredient Drugs

    not in the basket chart

    PPI. Dexlansoprazole 30 mg, 60 mg.
    CAPS.: 28. Tmt. of erosive reflux oesophagitis: One 60 mg cap. once dly. for up to 8 wks. Maint. of healed erosive reflux oesophagitis and maint. of relief of heartburn: One 30 mg cap. once dly. Sympt. non-erosive gastro-esoph. reflux disease (GERD): One 30 mg cap. once dly. for 4 wks. Control. studies did not extend beyond 6 mnths. in adults and 16 wks. in pts. 12-17 yrs. old.
    30mg: adult.& adolesc. aged 12 -17 yrs. for the follow.: Maint. of healed erosive reflux oesophagitis, maint. of relief of heartburn. Short-term tmt. of heartburn & acid regurgitate. assoc. with sympt. nonerosive gastro-esophageal reflux disease GERD. 60mg: adult.& adolesc. aged 12 -17 yrs: Tmt. of erosive reflux oesophagitis.
    C/I: Hypersens. Acute interstit. Nephrit. (AIN) has been reported with other PPIs, includ. lansoprazole of which dexlansoprazole is the R-enantiomer. Concom. use with rilpivirine-contain. products.